Protocol Ledger

NCT04888741 · Phase II · RECRUITING

Methods of T Cell Depletion Trial (MoTD)

Interventional Phase II clinical trial protocol NCT04888741 sponsored by University of Birmingham in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-02-22 Enrollment: 400 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04888741
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)400 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04888741
Protocol FieldVerified Registry Value
NCT IdentifierNCT04888741
Consolidated Lead SponsorUniversity of Birmingham
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment400 participants (ESTIMATED)
Registered Start Date2021-02-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04888741
Hospital Research SiteLocationSite Profile
University Hospital of WalesCardiff, United KingdomOpen Hospital Dossier ->
University College London HospitalLondon, United KingdomOpen Hospital Dossier ->
King's College HospitalLondon, United KingdomOpen Hospital Dossier ->
Hammersmith HospitalLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI